Todd Bazemore - 26 Oct 2022 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
President and Chief Operating Officer
Signature
/s/ Eric Trachtenberg, Attorney-in-Fact
Issuer symbol
KALA
Transactions as of
26 Oct 2022
Net transactions value
-$1,393
Form type
4
Filing time
28 Oct 2022, 16:15:39 UTC
Previous filing
29 Jun 2022
Next filing
06 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Sale $1,393 -214 -9.3% $6.51 2,097 26 Oct 2022 Direct F1, F2, F3, F4
holding KALA Common Stock 1 26 Oct 2022 By son
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.56, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3 Includes 367 unvested RSUs.
F4 The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

Remarks:

President and Chief Operating Officer